vs

Side-by-side financial comparison of AMERICAN AXLE & MANUFACTURING HOLDINGS INC (AXL) and GLOBUS MEDICAL INC (GMED). Click either name above to swap in a different company.

AMERICAN AXLE & MANUFACTURING HOLDINGS INC is the larger business by last-quarter revenue ($1.4B vs $826.4M, roughly 1.7× GLOBUS MEDICAL INC). GLOBUS MEDICAL INC runs the higher net margin — 17.0% vs -5.4%, a 22.5% gap on every dollar of revenue. On growth, GLOBUS MEDICAL INC posted the faster year-over-year revenue change (25.7% vs 0.2%). GLOBUS MEDICAL INC produced more free cash flow last quarter ($202.4M vs $54.7M). Over the past eight quarters, GLOBUS MEDICAL INC's revenue compounded faster (16.7% CAGR vs -7.2%).

American Axle & Manufacturing, Inc. (AAM), headquartered in Detroit, Michigan, is an American manufacturer of automobile driveline and drivetrain components and systems.

Globus Medical, Inc. is a publicly traded orthopedic medical device company headquartered in Audubon, Pennsylvania, United States. Globus is focused on the design, development, and commercialization of products that enable surgeons to promote healing in patients with musculoskeletal disorders.

AXL vs GMED — Head-to-Head

Bigger by revenue
AXL
AXL
1.7× larger
AXL
$1.4B
$826.4M
GMED
Growing faster (revenue YoY)
GMED
GMED
+25.5% gap
GMED
25.7%
0.2%
AXL
Higher net margin
GMED
GMED
22.5% more per $
GMED
17.0%
-5.4%
AXL
More free cash flow
GMED
GMED
$147.7M more FCF
GMED
$202.4M
$54.7M
AXL
Faster 2-yr revenue CAGR
GMED
GMED
Annualised
GMED
16.7%
-7.2%
AXL

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
AXL
AXL
GMED
GMED
Revenue
$1.4B
$826.4M
Net Profit
$-75.3M
$140.6M
Gross Margin
10.2%
68.4%
Operating Margin
-2.4%
20.5%
Net Margin
-5.4%
17.0%
Revenue YoY
0.2%
25.7%
Net Profit YoY
-449.6%
430.4%
EPS (diluted)
$-0.62
$1.01

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AXL
AXL
GMED
GMED
Q4 25
$1.4B
$826.4M
Q3 25
$1.5B
$769.0M
Q2 25
$1.5B
$745.3M
Q1 25
$1.4B
$598.1M
Q4 24
$1.4B
$657.3M
Q3 24
$1.5B
$625.7M
Q2 24
$1.6B
$629.7M
Q1 24
$1.6B
$606.7M
Net Profit
AXL
AXL
GMED
GMED
Q4 25
$-75.3M
$140.6M
Q3 25
$9.2M
$119.0M
Q2 25
$39.3M
$202.8M
Q1 25
$7.1M
$75.5M
Q4 24
$-13.7M
$26.5M
Q3 24
$10.0M
$51.8M
Q2 24
$18.2M
$31.8M
Q1 24
$20.5M
$-7.1M
Gross Margin
AXL
AXL
GMED
GMED
Q4 25
10.2%
68.4%
Q3 25
12.6%
67.2%
Q2 25
13.1%
66.6%
Q1 25
12.3%
67.3%
Q4 24
11.2%
59.9%
Q3 24
11.4%
56.8%
Q2 24
13.3%
58.7%
Q1 24
12.4%
60.2%
Operating Margin
AXL
AXL
GMED
GMED
Q4 25
-2.4%
20.5%
Q3 25
3.2%
17.9%
Q2 25
3.6%
10.2%
Q1 25
3.0%
16.2%
Q4 24
2.6%
9.2%
Q3 24
2.8%
7.7%
Q2 24
5.3%
7.9%
Q1 24
4.8%
1.3%
Net Margin
AXL
AXL
GMED
GMED
Q4 25
-5.4%
17.0%
Q3 25
0.6%
15.5%
Q2 25
2.6%
27.2%
Q1 25
0.5%
12.6%
Q4 24
-1.0%
4.0%
Q3 24
0.7%
8.3%
Q2 24
1.1%
5.0%
Q1 24
1.3%
-1.2%
EPS (diluted)
AXL
AXL
GMED
GMED
Q4 25
$-0.62
$1.01
Q3 25
$0.07
$0.88
Q2 25
$0.32
$1.49
Q1 25
$0.06
$0.54
Q4 24
$-0.11
$0.19
Q3 24
$0.08
$0.38
Q2 24
$0.15
$0.23
Q1 24
$0.17
$-0.05

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AXL
AXL
GMED
GMED
Cash + ST InvestmentsLiquidity on hand
$708.9M
$557.2M
Total DebtLower is stronger
$4.0B
Stockholders' EquityBook value
$640.0M
$4.6B
Total Assets
$6.7B
$5.3B
Debt / EquityLower = less leverage
6.31×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AXL
AXL
GMED
GMED
Q4 25
$708.9M
$557.2M
Q3 25
$714.1M
$18.8M
Q2 25
$586.5M
Q1 25
$549.2M
Q4 24
$552.9M
$890.1M
Q3 24
$542.5M
$71.9M
Q2 24
$519.9M
$82.5M
Q1 24
$469.8M
$80.4M
Total Debt
AXL
AXL
GMED
GMED
Q4 25
$4.0B
Q3 25
$2.6B
Q2 25
$2.6B
Q1 25
$2.6B
Q4 24
$2.6B
Q3 24
$2.6B
Q2 24
$2.7B
Q1 24
$2.7B
Stockholders' Equity
AXL
AXL
GMED
GMED
Q4 25
$640.0M
$4.6B
Q3 25
$718.4M
$4.4B
Q2 25
$673.0M
$4.3B
Q1 25
$596.3M
$4.1B
Q4 24
$562.8M
$4.2B
Q3 24
$616.3M
$4.1B
Q2 24
$609.6M
$4.0B
Q1 24
$621.4M
$3.9B
Total Assets
AXL
AXL
GMED
GMED
Q4 25
$6.7B
$5.3B
Q3 25
$5.3B
$5.1B
Q2 25
$5.3B
$5.0B
Q1 25
$5.1B
$4.7B
Q4 24
$5.1B
$5.3B
Q3 24
$5.3B
$5.1B
Q2 24
$5.3B
$5.0B
Q1 24
$5.4B
$4.9B
Debt / Equity
AXL
AXL
GMED
GMED
Q4 25
6.31×
Q3 25
3.61×
Q2 25
3.86×
Q1 25
4.38×
Q4 24
4.58×
Q3 24
4.28×
Q2 24
4.42×
Q1 24
4.40×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AXL
AXL
GMED
GMED
Operating Cash FlowLast quarter
$120.5M
$248.6M
Free Cash FlowOCF − Capex
$54.7M
$202.4M
FCF MarginFCF / Revenue
4.0%
24.5%
Capex IntensityCapex / Revenue
4.8%
5.6%
Cash ConversionOCF / Net Profit
1.77×
TTM Free Cash FlowTrailing 4 quarters
$155.1M
$588.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AXL
AXL
GMED
GMED
Q4 25
$120.5M
$248.6M
Q3 25
$143.3M
$249.7M
Q2 25
$91.9M
$77.9M
Q1 25
$55.9M
$177.3M
Q4 24
$151.2M
$210.3M
Q3 24
$143.6M
$203.7M
Q2 24
$142.8M
$54.3M
Q1 24
$17.8M
$52.4M
Free Cash Flow
AXL
AXL
GMED
GMED
Q4 25
$54.7M
$202.4M
Q3 25
$79.2M
$213.9M
Q2 25
$34.6M
$31.3M
Q1 25
$-13.4M
$141.2M
Q4 24
$73.2M
$193.2M
Q3 24
$70.4M
$161.7M
Q2 24
$94.0M
$26.5M
Q1 24
$-30.2M
$23.8M
FCF Margin
AXL
AXL
GMED
GMED
Q4 25
4.0%
24.5%
Q3 25
5.3%
27.8%
Q2 25
2.3%
4.2%
Q1 25
-0.9%
23.6%
Q4 24
5.3%
29.4%
Q3 24
4.7%
25.8%
Q2 24
5.8%
4.2%
Q1 24
-1.9%
3.9%
Capex Intensity
AXL
AXL
GMED
GMED
Q4 25
4.8%
5.6%
Q3 25
4.3%
4.7%
Q2 25
3.7%
6.2%
Q1 25
4.9%
6.0%
Q4 24
5.6%
2.6%
Q3 24
4.9%
6.7%
Q2 24
3.0%
4.4%
Q1 24
3.0%
4.7%
Cash Conversion
AXL
AXL
GMED
GMED
Q4 25
1.77×
Q3 25
15.58×
2.10×
Q2 25
2.34×
0.38×
Q1 25
7.87×
2.35×
Q4 24
7.94×
Q3 24
14.36×
3.93×
Q2 24
7.85×
1.71×
Q1 24
0.87×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

AXL
AXL

Driveline$748.4M54%
Other$345.7M25%
Metal Forming$289.8M21%

GMED
GMED

Other$391.8M47%
Nevro Merger Agreement$293.6M36%
Enabling Technologies$141.0M17%

Related Comparisons